Understanding Late-Onset Interstitial Lung Disease in Systemic Sclerosis: Implications for Clinical Practice and Trial Design.
作者信息
Volkmann Elizabeth R
机构信息
David Geffen School of Medicine, University of California, Los Angeles.
出版信息
Arthritis Rheumatol. 2025 Apr;77(4):380-382. doi: 10.1002/art.43053. Epub 2024 Dec 1.
Abstract
摘要
相似文献
1
Understanding Late-Onset Interstitial Lung Disease in Systemic Sclerosis: Implications for Clinical Practice and Trial Design.系统性硬化症中迟发性间质性肺疾病的认识：对临床实践和试验设计的启示
Arthritis Rheumatol. 2025 Apr;77(4):380-382. doi: 10.1002/art.43053. Epub 2024 Dec 1.
2
Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis.胸部淋巴结病作为基线访视时无肺部受累的系统性硬化症患者间质性肺疾病发病的可能预测指标：一项回顾性分析。
J Scleroderma Relat Disord. 2020 Oct;5(3):210-218. doi: 10.1177/2397198320923545. Epub 2020 Jun 2.
3
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.尼达尼布作为系统性硬化症相关间质性肺病治疗方法的评估原理。
J Scleroderma Relat Disord. 2019 Oct;4(3):212-218. doi: 10.1177/2397198319841842. Epub 2019 Apr 21.
4
Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.系统性硬皮病相关间质性肺病的治疗：现有和新兴疗法的综述。
Ann Am Thorac Soc. 2016 Nov;13(11):2045-2056. doi: 10.1513/AnnalsATS.201606-426FR.
5
Determining progression of scleroderma-related interstitial lung disease.确定硬皮病相关间质性肺疾病的进展情况。
J Scleroderma Relat Disord. 2019 Feb;4(1):62-70. doi: 10.1177/2397198318816915. Epub 2018 Dec 17.
6
Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials.系统性硬化症相关间质性肺疾病中用于临床实践和临床试验的患者报告结局指标
J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):48-60. doi: 10.1177/2397198320904178. Epub 2020 Mar 5.
7
Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group.间质性肺疾病与系统性硬化症患者患肺癌风险增加相关：来自加拿大硬皮病研究组的纵向数据
J Scleroderma Relat Disord. 2018 Oct;3(3):221-227. doi: 10.1177/2397198318766825. Epub 2018 Apr 10.
8
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.CONQUEST研究设计，这是一项新颖的、随机、安慰剂对照的2b期平台临床试验，旨在研究针对早期活动性系统性硬化症合并间质性肺病患者的新治疗方法。
J Scleroderma Relat Disord. 2024 Nov 5:23971983241278079. doi: 10.1177/23971983241278079.
9
Physician-patient communication in the treatment of systemic sclerosis-associated interstitial lung disease: A narrative review and recommendations.系统性硬化症相关间质性肺病治疗中的医患沟通：一项叙述性综述与建议
J Scleroderma Relat Disord. 2025 Mar 20:23971983251324803. doi: 10.1177/23971983251324803.
10
Pathogenesis of systemic sclerosis associated interstitial lung disease.系统性硬化症相关间质性肺病的发病机制。
J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):6-16. doi: 10.1177/2397198320903867. Epub 2020 Mar 5.
本文引用的文献
1
Characterization of Incident Interstitial Lung Disease in Late Systemic Sclerosis.晚期系统性硬化症中偶发性间质性肺病的特征
Arthritis Rheumatol. 2025 Apr;77(4):450-457. doi: 10.1002/art.43051. Epub 2025 Jan 7.
2
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.2023 年美国风湿病学会（ACR）/美国胸科学会（CHEST）系统性自身免疫性风湿病患者间质性肺病筛查和监测指南。
Arthritis Rheumatol. 2024 Aug;76(8):1201-1213. doi: 10.1002/art.42860. Epub 2024 Jul 8.
3
Enrichment Strategies for Systemic Sclerosis-Interstitial Lung Disease Trials.系统性硬化症-间质性肺病试验的富集策略
Am J Respir Crit Care Med. 2024 May 1;209(9):1067-1068. doi: 10.1164/rccm.202401-0246ED.
4
Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort.真实世界两中心队列中系统性硬化症相关间质性肺病未经治疗患者的特征和疾病进程。
RMD Open. 2024 Jan 9;10(1):e003658. doi: 10.1136/rmdopen-2023-003658.
5
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.系统性硬化症相关间质性肺疾病的治疗：循证推荐。美国胸科学会临床实践指南。
Am J Respir Crit Care Med. 2024 Jan 15;209(2):137-152. doi: 10.1164/rccm.202306-1113ST.
6
Systemic sclerosis.系统性硬化症。
Lancet. 2023 Jan 28;401(10373):304-318. doi: 10.1016/S0140-6736(22)01692-0. Epub 2022 Nov 25.
7
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.从欧洲硬皮病试验和研究中探讨系统性硬化症进行性间质性肺病的队列富集策略。
Chest. 2023 Mar;163(3):586-598. doi: 10.1016/j.chest.2022.09.044. Epub 2022 Oct 14.
8
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.SENSCIS 试验中系统性硬化症相关间质性肺病患者的呼吸困难和咳嗽。
Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408. doi: 10.1093/rheumatology/keac091.
9
Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis.用于检测早期弥漫性皮肤系统性硬化症成人间质性肺病的肺功能测试的性能特征。
Arthritis Rheumatol. 2020 Nov;72(11):1892-1896. doi: 10.1002/art.41415. Epub 2020 Sep 22.
10
Role of imaging in progressive-fibrosing interstitial lung diseases.影像学在进行性纤维性间质性肺疾病中的作用。
Eur Respir Rev. 2018 Dec 21;27(150). doi: 10.1183/16000617.0073-2018. Print 2018 Dec 31.
Zotero 插件